Inhibition of Hepatitis C Virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor

Journal of Medical Virology

Volumn 65, Issue 4, 2001, Pages 671-680

  Heintges, Tobias ^a,b,d   Encke, Jens ^a,b,c   Putlitz, Jasper Zu ^a   Wands, Jack R ^a  

^a BROWN UNIVERSITY   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antisense oligodeoxynucleotides; Cell culture; HCV; NS3 protease function; Protease inhibitors

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CHYMOSTATIN; LUCIFERASE; PROTEINASE INHIBITOR; PROTEINASE NS3; SERINE PROTEINASE; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; OPEN READING FRAME; RNA TRANSLATION; VIRUS REPLICATION;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HEPACIVIRUS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTEASE INHIBITORS; PROTEIN BIOSYNTHESIS; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

ANIMALIA; HEPATITIS C VIRUS;

EID: 0035214935     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2089     Document Type: Article

References (55)

1. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides
2. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions
3. Kinetic and structural analyses of hepatitis C virus polyprotein processing
4. Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks
5. An in vitro assay for hepatitis C virus NS3 serine proteinase
6. A hitchhiker's guide to antisense and nonantisense biochemical pathways
7. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model
8. Total chemical synthesis of the 3′ untranslated region of the hepatitis C virus with long oligodeoxynucleotides
9. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins
10. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
11. Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites
12. Expression and identifcation of hepatitis C virus polyprotein cleavage products
13. NS3-4A of hepatitis C virus is a chymotrypsin-like protease
14. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes
15. A point mutation abolishes the helicase but not the nucleoside triphosphatase activity of hepatitis C virus NS3 protein
16. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus
17. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus
18. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products
19. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide
20. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: The crystal structure provides insights into the mode of unwinding
21. Specificity of the hepatitis C virus NS3 serine protease: Effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing
22. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA
23. Combination therapy for hepatitis C infection
24. Hepatitis C virus NS3 serine proteinase: Trans-cleavage requirements and processing kinetics
25. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
26. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site
27. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
28. Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells
29. Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium
30. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides
31. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
32. Steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain
33. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: Properties of the NS5A-associated kinase
34. Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: In vitro translation assay
35. Human growth hormone as a reporter gene in regulation studies employing transient gene expression
36. In vitro activity of hepatitis C virus protease NS3 purified from recombinant baculovirus-infected Sf9 cells
37. Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography
38. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes
39. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3)
40. An enzyme-linked immunosorbent assay for detecting proteolytic activity of hepatitis C virus proteinase
41. Hepatitis C virus polyprotein processing: Kinetics and mutagenic analysis of serine proteinase-dependent cleavage
42. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing
43. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs
44. NS3 is a serine protease required for processing of hepatitis C virus polyprotein
45. Substrate specificity of the hepatitis C virus serine protease NS3
46. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides
47. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence
48. Antiviral effects of antisense RNA on hepatitis C virus RNA translation and expression
49. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 A resolution structure m a hexagonal crystal form
50. In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice
51. Structure of the hepatitis C virus RNA helicase domain
52. The use of antisense and other molecular approaches to therapy of chronic viral hepatitis
53. On finding all suboptimal foldings of an RNA molecule